ArticleInsights into imaging2025
MRI-based risk stratification for predicting overall survival in pancreatic ductal adenocarcinoma.
Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeTo develop and validate a magnetic resonance imaging (MRI)-based pancreatic risk stratification model (M-PRiSM) for prognosis prediction and therapy guidance in pancreatic ductal adenocarcinoma (PDAC). MATERIALS AND
methodsIn this retrospective multicenter study, a total of 540 patients with PDAC were enrolled. A Cox proportional hazards model was used to identify significant clinical-radiological predictors and develop an M-PRiSM risk score system. The performance of the model was assessed using Harrell's C-index, time-dependent area under the curve (AUC), and calibration curves, and was compared with existing clinical prediction metrics, including the 8
results540 PDAC patients were split into a development cohort (n = 282) and an internal validation cohort (n = 122), with 136 patients forming external cohort A (n = 80) and B (n = 56). The model, incorporating CA19-9 (hazard ratio (HR), 1.604, p = 0.047), margin (HR, 1.918, p = 0.001), tumor size (HR, 1.308, p = 0.003), and venous enhancement ratio (VER) (HR, 0.605, p = 0.047), was developed, showing superior predictive accuracy for OS with C-indexes of 0.73, 0.70, and 0.70, and 0.68 across four cohorts. The model outperformed the 8th AJCC staging and CA19-9 alone across validation cohorts (p < 0.001). High-risk patients exhibit the worst overall survival (OS) and a higher frequency of adverse pathological features, but benefited significantly from adjuvant therapy, with improved survival outcomes.
conclusionThe M-PRiSM model effectively predicts postoperative OS and identifies PDAC patients likely to benefit from adjuvant treatment. CRITICAL RELEVANCE STATEMENT: The M-PRiSM model, utilizing MRI and clinical features, enables preoperative risk stratification for overall survival in pancreatic ductal adenocarcinoma, offering a generalizable tool to guide personalized adjuvant therapy and enhance prognostic assessment. KEY POINTS: The M-PRiSM model can effectively predict pancreatic ductal adenocarcinoma survival. The M-PRiSM model showed strong generalizability in external validations. The M-PRiSM model stratifies patients for guiding adjuvant therapy for improved outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.